Topic

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Videos

As Thermo Fisher’s Jennifer Cannon explains in this first part of a two-part interview, the collaboration is intended to help improve the speed and success of drug development.

Thermo Fisher Launches OpenAI Partnership at CPHI Frankfurt 2025: Part One

Life sciences CEOs are boosting AI spending, focusing on workforce upskilling, and tackling ethical challenges to drive innovation and product development.

KPMG CEO Outlook: How Pharma Is Navigating AI, Regulatory Demands, and Supply Chain Risk

 is vice-president, Product Management for AI & Data at 

, based in London. A data science actuary, he has built his career in fintech and health-tech, and specializes in AI-powered, data-driven, yet human-centric product innovation. He previously led an AstraZeneca digital incubator and today remains on the board of a health charity, Scleroderma & Raynaud's UK (SRUK), which is dedicated to improving the lives of people affected by those conditions in the UK.

Articles

In the conclusion of this three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part Three: Tapping Agentic AI’s Potential

In this continuation of a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part Two: Agentic AI’s Adoption in Life Sciences

Jennifer Markarian is a contributing editor for 

Advances in digital technologies offer effective data handling for bio/pharma manufacturing.

Optimizing Data Use for Digital Transformation

In a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part One: The Evolution of AI

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet

Survey responses indicate that bio/pharma faces tariff-driven rising costs and supply strain, with firms aiming to boost compliance and diversification and seeking stable trade and R&D support.

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Help us get a better picture of how new tariffs and trade policy have impacted you and your organization.

Survey: Impacts of Tariffs and Trade Policy on the Bio/pharmaceutical Industry

Lack of skills in the AI realm was a distant second among those surveyed about the biggest barrier to innovation while using the technology.

Data and Artificial Intelligence